RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Jan Willem B. de Groot(Isala), Robert M.W. Hofstra(Erasmus MC)
Cited by 357
Related Papers
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
|The Lancet Oncology|2023|168
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
|European Journal of Cancer|2019|81